文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

半剂量与半时间光动力疗法治疗中心性浆液性脉络膜视网膜病变

Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.

作者信息

Liu Hsin-Yu, Yang Chang-Hao, Yang Chung-May, Ho Tzyy-Chang, Lin Chang-Ping, Hsieh Yi-Ting

机构信息

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.

出版信息

Am J Ophthalmol. 2016 Jul;167:57-64. doi: 10.1016/j.ajo.2016.04.001. Epub 2016 Apr 12.


DOI:10.1016/j.ajo.2016.04.001
PMID:27084002
Abstract

PURPOSE: To compare the efficacy of half-dose vs half-time photodynamic therapy (PDT) guided by fluorescein angiography (FA) for the treatment of central serous chorioretinopathy (CSC). DESIGN: Two-center, retrospective, comparative case series. METHODS: Sixty-one eyes with acute or chronic CSC involving fovea were recruited; 35 eyes received half-dose PDT and 26 eyes received half-time PDT. Improvement in best-corrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence tomography (OCT), and recurrence of CSC after PDT were compared between the 2 groups. RESULTS: The mean follow-up time after PDT was 14.8 ± 13.3 months. Both groups showed significant improvement in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times). Multiple regression analysis showed that PDT type was not correlated with visual improvement (P > .05 for all times). All eyes that received half-time PDT showed complete resolution of SRF within 6 months after PDT, but 3 eyes that received half-dose PDT had persistent SRF before loss to follow-up at months 5, 7, and 8 (P = .21 between 2 groups). Three of 32 eyes in the half-dose group and 2 of 26 eyes in the half-time group had recurrence of CSC during follow-up; all recurrent cases had complete SRF resolution after another PDT treatment. No adverse systemic or ocular side effects were observed in any cases. CONCLUSIONS: Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and showed similar efficacy in visual improvement and SRF resolution.

摘要

目的:比较荧光素血管造影(FA)引导下的半剂量与半时间光动力疗法(PDT)治疗中心性浆液性脉络膜视网膜病变(CSC)的疗效。 设计:两中心、回顾性、比较性病例系列研究。 方法:招募61只累及黄斑中心凹的急性或慢性CSC患眼;35只眼接受半剂量PDT治疗,26只眼接受半时间PDT治疗。比较两组治疗后最佳矫正视力(BCVA)的改善情况、光学相干断层扫描(OCT)显示的视网膜下液(SRF)消退情况以及PDT治疗后CSC的复发情况。 结果:PDT治疗后的平均随访时间为14.8±13.3个月。两组在PDT治疗后1、3、6和12个月时BCVA均有显著改善(所有时间点P<0.05)。多元回归分析显示,PDT类型与视力改善无关(所有时间点P>0.05)。所有接受半时间PDT治疗的患眼在PDT治疗后6个月内SRF均完全消退,但3只接受半剂量PDT治疗的患眼在第5、7和8个月失访前SRF持续存在(两组之间P=0.21)。半剂量组32只眼中有3只、半时间组26只眼中有2只在随访期间CSC复发;所有复发病例在再次接受PDT治疗后SRF均完全消退。所有病例均未观察到全身性或眼部不良副作用。 结论:半剂量和半时间FA引导下的PDT治疗CSC均有效且安全,在视力改善和SRF消退方面疗效相似。

相似文献

[1]
Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.

Am J Ophthalmol. 2016-7

[2]
Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.

Acta Ophthalmol. 2016-3

[3]
One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Ophthalmology. 2014-11-18

[4]
COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2017-2

[5]
Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Am J Ophthalmol. 2014-1-30

[6]
A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.

Am J Ophthalmol. 2016-10

[7]
Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2018-11

[8]
[Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].

Zhonghua Yan Ke Za Zhi. 2016-5

[9]
Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Trans Am Ophthalmol Soc. 2015

[10]
Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.

Ophthalmology. 2014-1-16

引用本文的文献

[1]
Treatment of central serous chorioretinopathy: new options for an old disease.

Eye (Lond). 2025-7-4

[2]
Photodynamic treatment without verteporfin in chronic central serous chorioretinopathy.

BMC Ophthalmol. 2025-5-23

[3]
Giant retinal pigment epithelial tear following photodynamic therapy for the bullous variant of central serous chorioretinopathy: A case report.

Medicine (Baltimore). 2024-4-19

[4]
Fluorescein versus Indocyanine Green Angiography Guided Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

J Ophthalmic Vis Res. 2024-3-14

[5]
Early versus delayed photodynamic therapy for chronic central serous chorioretinopathy.

Int Ophthalmol. 2023-11

[6]
Two Cases of Chronic Central Serous Chorioretinopathy Successfully Treated with Systemic Interferon Alpha.

Ocul Immunol Inflamm. 2024-9

[7]
Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.

PLoS One. 2023

[8]
Factors related to changes in visual symptoms after successful photodynamic therapy in central serous chorioretinopathy.

PLoS One. 2023

[9]
Central serous chorioretinopathy: Treatment.

Taiwan J Ophthalmol. 2022-11-28

[10]
The Contemporary Role of Photodynamic Therapy in the Treatment of Pachychoroid Diseases.

J Ophthalmol. 2021-10-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索